Sun Pharma Advanced Research Company informs about company updates

01 Apr 2017 Evaluate

Sun Pharma Advanced Research Company has informed that the Company has received an intimation from Shanghvi Finance, a Promoter Group Company, stating that pursuant to an internal restructuring of entities owned / controlled by Dilip Shanghvi, Promoter of SPARC, (DSS Group), they have acquired the controlling share capital of some of the entities forming part of the DSS Group (Holding Companies) from the Promoter of SPARC and his wife on March 30, 2017. Presently, the Holding Companies in turn collectively hold the controlling stake in some of the DSS Group entities, which in turn holds shares in the Company. Consequent to the above acquisition, Shanghvi Finance have gained direct/indirect control on 52.336% of the total share capital of the Company, thereby making Sun Pharma Advanced Research Company its subsidiary in terms of section 2(87)(ii) of the Companies Act, 2013. However, it is pertinent to note that Dilip Shanghvi, will continue to be Promoter of the Company.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma Adv. Res Share Price

131.45 0.35 (0.27%)
18-Dec-2025 10:35 View Price Chart
Peers
Company Name CMP
Syngene Internation. 652.45
Indegene 528.35
CMS Info Systems 346.10
Sagility 51.08
Smartworks Coworking 471.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×